Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Phase I Study of KW-0761 in Relapsed Patients With CCR4-Positive ATL and PTCL

This study has been completed.
Information provided by (Responsible Party):
Kyowa Hakko Kirin Co., Ltd Identifier:
First received: July 20, 2006
Last updated: October 17, 2012
Last verified: October 2012
This is a Phase I label dose escalation study of KW-0761 in relapsed patients with CCR4 positive Adult T-Cell Leukemia-Lymphoma (ATL) and Peripheral T-Cell lymphoma (PTCL).

Condition Intervention Phase
Adult T-Cell Leukemia and Lymphoma (ATL)
Adult Peripheral T-Cell Lymphoma (PTCL)
Drug: KW-0761
Phase 1

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Phase I Dose Escalation Study of KW-0761 in Patients With Relapsed Adult T-Cell Lymphoma (ATL) and Peripheral T-Cell Lymphoma (PTCL)

Resource links provided by NLM:

Further study details as provided by Kyowa Hakko Kirin Co., Ltd:

Primary Outcome Measures:
  • Incidence of Dose-Limiting Toxicities (DLTs) [ Time Frame: 28 days ]
    Subjects who were properly monitored for DLTs were to be analyzed to determine the number of subjects with a DLT by dose level.

  • Maximum Tolerated Dose (MTD) [ Time Frame: 28 days ]
    The dose level at which Dose-Limiting Toxicity (DLT) was recognized was to be regarded as Maximum Tolerated Dose (MTD), and the dose level below MTD by one level was to be regarded as the recommended dose level (when MTD was not reached, 1.0 mg/kg was to be regarded as the recommended dose level) and 3 more subjects were to be newly added to the recommended dose level.

  • Pharmacokinetics-Plasma KW-0761 Concentrations [ Time Frame: 0-7 days post final dose ]
    Plasma KW-0761 concentrations were to be summarized in tabular form with the descriptive statistics on a dose-by-dose basis. Individual and mean (+ standard deviation) plasma KW-0761 concentrations on an actual or logarithmic scale were to be plotted against the time of blood sampling.

  • Pharmacokinetics-Pharmacokinetic Parameters of KW-0761 (AUC0-7 Days) [ Time Frame: 0-7 days post final dose ]
    The pharmacokinetic parameters of the subjects were to be individually calculated, and their descriptive statistics were to be calculated on a dose-by-dose basis.

  • Pharmacokinetics-Pharmacokinetic Parameters of KW-0761 (t1/2) [ Time Frame: 0 to 28 days post final dose and follow-up examinations (1 month and 2 months after the end of the post-dosing observation period). ]
    The pharmacokinetic parameters of the subjects were to be individually calculated, and their descriptive statistics were to be calculated on a dose-by-dose basis.

Secondary Outcome Measures:
  • Antitumor Effect [ Time Frame: 50 days ]
    The antitumor response criteria (Complete response (CR), partial response (PR), stable disease (SD), progressive disease (PD)) were created based on the criteria for non-Hodgkin's lymphoma and chronic lymphocytic leukemia provided in the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology as well as the criteria for non-Hodgkin's lymphoma by the Lymphoma Study Group of the Japan Clinical Oncology Group (JCOG-LSG).

  • Time to Progression (TTP) [ Time Frame: Baseline to response ]
    TTP was defined as the period from the day starting the first KW-0761 dosing to the day of PD identification (or the day of death if the subject died before PD was documented). Subjects were to be censored at the time of starting post-treatment, if it was started before PD identification.

Enrollment: 16
Study Start Date: February 2007
Study Completion Date: October 2008
Primary Completion Date: October 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
Drug: KW-0761
IV administration at 4 escalating dose levels.

Detailed Description:
This is a Phase I open-label dose escalation study of KW-0761 in relapsed patients with CCR4 positive Adult T-Cell Leukemia-Lymphoma (ATL) and Peripheral T-Cell Lymphoma (PTCL). This study is designed to evaluate safety, pharmacokinetics, immunogenicity and preliminary efficacy. Enrollment will proceed until a maximum tolerated dose (MTD) and a recommended Phase II dose (RPIID) have been established.

Ages Eligible for Study:   20 Years to 69 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

1. Histologically confirmed diagnosis of a CCR4-positive ATL and PTCL that is any of the following:

A. ATL (Adult T-Cell Leukemia-Lymphoma)

  • Seropositive for anti-Human T-lymphotrophic Virus type-I (HTLV-I) antibody;
  • Acute, Lymphoma, or Chronic phase with high-risk factors (within 14 days before the study entry);

B. PTCL (Peripheral T-Cell Lymphoma)

  • Includes Mycosis Fungoides and Sezary Syndrome;

    2: Relapsed to the latest standard chemotherapy;

    3: Received at least one prior chemotherapy;

    4: After 4 weeks from a prior therapy;

    5: Have measurable disease;

    6:Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0 or 1;

    7: Male or female, at least 20 years and not older than 70 years of age;

    8: Signed written informed consent;

    9: Stay in hospital for 4 weeks;

    10: HBs antigen: negative, HBV-DNA: below the limit of quantification (within 14 days before the study entry);

    11: Adequate bone marrow, hepatic and cardiac function including the followings:

  • Neutrophil count ≥ 1,500 /mm3,
  • Platelets ≥ 75,000 /mm3,
  • Hemoglobin ≥ 8.0 g/dL
  • Serum creatinine ≤ 1.5 x ULN;
  • Serum SGOT (AST) and SGPT (ALT) ≤ 2.5 x ULN (≤ 5.0 x ULN if considered due to disease involvement in liver);
  • Serum bilirubin ≤ 1.5 x ULN (≤ 3.0 x ULN if considered due to disease involvement in liver)
  • Serum calcium ≤ 11.0 mg/dL
  • PaO2 ≥ 65 mmHg or SaO2 ≥ 90%
  • No clinically significant Electrocardiogram abnormality
  • Left Ventricular Ejection Fraction ≥ 50% [by ECHO or MUGA]

Exclusion Criteria:

  1. Co-existing active infection or any co-existing medical condition that may compromise the safety of patients during the study, affect the patient's ability to complete the study, or interfere with interpretation of study results;
  2. Active tuberculosis;
  3. Prior stem cell transplantation;
  4. Myocardial infarction (within 12 months prior to the study entry);
  5. Concurrent acute or chronic hepatitis, or cirrhosis;
  6. Anti-HCV: positive, Anti-HIV: positive
  7. Concurrent active malignant disease;
  8. Known allergic reaction to antibody therapy;
  9. Concomitant treatment with systemic steroids;
  10. Prior and Concurrent psychiatric disorder including dementia, epilepsy or any other CNS diseases;
  11. Evidence of CNS metastasis at baseline;
  12. Prior and Concurrent spinal cord disease;
  13. Radiation therapy for bulky mass disease at the time of study entry or considered to require radiation therapy during the study;
  14. Female patients who are pregnant or breast feeding;
  15. Female patients of childbearing potential, unwilling to use an approved, effective means of contraception in accordance with the institution's standards;
  16. Treatment with any other investigational agent within the 4 months prior to study entry;
  17. For any reason is judged by the Investigator to be inappropriate for study participation, including an inability to communicate or cooperate with the Investigator.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00355472

Tokyo, Japan
Sponsors and Collaborators
Kyowa Hakko Kirin Co., Ltd
Study Director: Study Director Kyowa Hakko Kirin Co., Ltd
  More Information

Responsible Party: Kyowa Hakko Kirin Co., Ltd Identifier: NCT00355472     History of Changes
Other Study ID Numbers: 0761-0501
Study First Received: July 20, 2006
Results First Received: August 7, 2012
Last Updated: October 17, 2012

Keywords provided by Kyowa Hakko Kirin Co., Ltd:
Adult T-Cell Leukemia
Adult Peripheral T-Cell Lymphoma

Additional relevant MeSH terms:
Lymphoma, T-Cell
Lymphoma, T-Cell, Peripheral
Leukemia-Lymphoma, Adult T-Cell
Lymphoma, Non-Hodgkin
Leukemia, T-Cell
Neoplasms by Histologic Type
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Leukemia, Lymphoid
Leukemia processed this record on May 22, 2017